These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11093139)

  • 1. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock.
    Delgado M; Gomariz RP; Martinez C; Abad C; Leceta J
    Eur J Immunol; 2000 Nov; 30(11):3236-46. PubMed ID: 11093139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Protective effects of vasoactive intestinal peptide on intestinal lesions induced by endotoxic shock in rat].
    Zhang YC; Yang LP; Tang DH; Zhang YM
    Zhonghua Er Ke Za Zhi; 2006 May; 44(5):369-73. PubMed ID: 16780716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.
    Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP
    J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
    Gonzalez-Rey E; Delgado M
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D; Delgado M
    Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock.
    Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP
    J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.
    Delgado M; Abad C; Martinez C; Juarranz MG; Arranz A; Gomariz RP; Leceta J
    J Mol Med (Berl); 2002 Jan; 80(1):16-24. PubMed ID: 11862320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D; Delgado M
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
    Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
    Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.
    Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP
    J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.
    Voice JK; Grinninger C; Kong Y; Bangale Y; Paul S; Goetzl EJ
    J Immunol; 2003 Jan; 170(1):308-14. PubMed ID: 12496414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.